Mantle Cell Lymphoma (MCL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Mantle Cell Lymphoma (MCL) Market Outlook

Thelansis’s “Mantle Cell Lymphoma (MCL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mantle Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Mantle Cell Lymphoma (MCL) Overview

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs). Mantel cell lymphoma is primarily driven by a chromosomal translocation denoted as t(11;14) (q13;q32), wherein the CCND1 gene becomes juxtaposed with the gene responsible for encoding heavy chain immunoglobulins. This event leads to an abnormal surge in the expression of cyclin D1, a crucial cell cycle regulator, within the lymphoma cells' nucleus. Mantle cell lymphoma primarily afflicts middle-aged adults, with a notable peak around age 65 (spanning from 35 to 85 years). Males experience a higher incidence, with a male-to-female ratio of 4:1. Upon diagnosis, most patients exhibit an extensively disseminated form of the disease. This condition is frequently accompanied by widespread adenopathy (observed in 90% of cases), gastrointestinal complications (occurring in 60% of cases), and bone marrow infiltration (ranging from 55% to 80% of cases). Additionally, individuals may manifest symptoms such as fever and a decline in general well-being, characterized by fatigue, loss of appetite, and weight loss. Differential diagnoses should consider conditions such as follicular lymphoma and other lymphoma subtypes. Current treatments yield complete responses in only a minority of patients (around 30%). The literature reports a median overall survival duration of 3-5 years for individuals with this condition.

• Mantle cell lymphoma predominantly affects individuals between the ages of 60 and 70, with men being three times more susceptible than women.
• In the United States, approximately 5,970 new cases of mantle cell lymphoma were diagnosed in 2019, constituting roughly 5 to 7% of all cases of non-Hodgkin lymphoma (NHL).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: